A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2019
Price : $35 *
At a glance
- Drugs AMG 232 (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 27 Jun 2019 Planned number of patients changed from 80 to 46.
- 04 Jun 2019 According to trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology, as of now 3 patients have been enrolled to cohort A and 2 patients in cohort B at dose level 1. The first patient has a tumor with WT p53 gene and has completed protocol treatment safely.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.